(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 19.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Mirum Pharmaceuticals's revenue in 2025 is $429,161,000.On average, 6 Wall Street analysts forecast MIRM's revenue for 2025 to be $25,515,901,862, with the lowest MIRM revenue forecast at $25,124,349,641, and the highest MIRM revenue forecast at $26,102,979,005. On average, 6 Wall Street analysts forecast MIRM's revenue for 2026 to be $31,260,526,559, with the lowest MIRM revenue forecast at $28,801,745,402, and the highest MIRM revenue forecast at $32,810,709,632.
In 2027, MIRM is forecast to generate $37,037,152,637 in revenue, with the lowest revenue forecast at $33,518,507,841 and the highest revenue forecast at $39,310,958,778.